Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 10;15(22):5355.
doi: 10.3390/cancers15225355.

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer

Irina M Cazacu  1   2 , Ben S Singh  3 , Rachael M Martin-Paulpeter  4 , Sam Beddar  4 , Stephen Chun  5 , Emma B Holliday  5 , Albert C Koong  5 , Prajnan Das  5 , Eugene J Koay  5 , Cullen Taniguchi  5 , Joseph M Herman  6 , Manoop S Bhutani  3
Affiliations

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer

Irina M Cazacu et al. Cancers (Basel). .

Abstract

Accurate delivery of stereotactic body radiotherapy (SBRT) to pancreatic tumors relies on successful EUS-guided placement of fiducial markers. The aim of this study is to report the technical feasibility and safety of EUS-guided fiducial placement and to evaluate the characteristics and technical benefit of SBRT in a cohort of patients with pancreatic cancer (PC). A retrospective chart review was performed for all (n = 82) PC patients referred for EUS-guided fiducial placement by a single endosonographer at a tertiary cancer center. Data regarding EUS-related technical details, SBRT characteristics, adverse events, and continuous visibility of fiducials were recorded and analyzed. Most patients included in the study had either locally advanced disease (32 patients, 39%) or borderline resectable disease (29 patients, 35%). Eighty-two PC patients underwent the placement of 230 fiducial markers under EUS guidance. The technical success rate of the fiducial placement was 98%. No immediate EUS-related adverse events were reported. The average time to the simulation CT after fiducial placement was 3.1 days. Of the 216 fiducial markers used for the SBRT delivery, 202 fiducial markers were visible on both the simulation CT and the cone beam CT scan. A median dose of 40cGY was given to all the patients in five fractions. Of these, 41% of the patients reported no SBRT-related toxicities during the follow-up. Fatigue and nausea were the most reported SBRT-related toxicities, which were seen in 35% of the patients post-SBRT. Our results demonstrate that EUS-guided fiducial placement is safe and effective in target volume delineation, facilitating SBRT delivery in PC patients. Further clinical trials are needed to determine the SBRT-related survival benefits in patients with pancreatic cancer.

Keywords: SBRT; endoscopic ultrasound; fiducial markers; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Endoscopic ultrasound view of fiducial marker in pancreatic neck tumor (red arrow).
Figure 2
Figure 2
(a) Fiducial markers seen in pre-treatment CT simulation; (b) same fiducial markers as seen on cone beam CT imaging for radiation dosage planning.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stoffel E.M., Brand R.E., Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Gastroenterology. 2023;164:752–765. doi: 10.1053/j.gastro.2023.02.012. - DOI - PMC - PubMed
    1. Versteijne E., Suker M., Groothuis K., Akkermans-Vogelaar J.M., Besselink M.G., Bonsing B.A., Buijsen J., Busch O.R., Creemers G.-J.M., van Dam R.M. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phae III PREOPANC trial. J. Clin. Oncol. 2020;38:1763. doi: 10.1200/JCO.19.02274. - DOI - PMC - PubMed
    1. Katz M.H., Crane C.H., Varadhachary G. Management of borderline resectable pancreatic cancer. Semin. Radiat. Oncol. 2014;24:105–112. doi: 10.1016/j.semradonc.2013.11.006. - DOI - PubMed
    1. Murphy J.E., Wo J.Y., Ryan D.P., Jiang W., Yeap B.Y., Drapek L.C., Blaszkowsky L.S., Kwak E.L., Allen J.N., Clark J.W. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2018;4:963–969. doi: 10.1001/jamaoncol.2018.0329. - DOI - PMC - PubMed
    1. Tempero M.A. NCCN guidelines updates: Pancreatic cancer. J. Natl. Compr. Cancer Netw. 2019;17:603–605. - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources